Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

Inclusion Criteria: * Subjects are candidates for a corneal transplant and are at increased immunological risk for graft failure, as evidenced by one or more of the following: * ≥ 1 quadrant deep corneal vascularization * verifiable history of graft failure due to rejection * position of graft is \< 1 mm from the limbus Exclusion Criteria: * Any condition that would greatly increase the risk of non-rejection graft failure such as Stevens-Johnson syndrome, xerophthalmia or severe exposure keratitis. * Schirmer's test ≤ 5 mm in 1 minute * Clinical evidence of limbal stem cell deficiency * History of or active herpes simplex virus keratitis or other acute corneal infection * Subjects who have had \> 3 failed grafts in the study eye * Uncontrolled glaucoma as evidenced by an intraocular pressure of \>21 mmHg while on maximal medical therapy * Clinically suspected or confirmed ocular lymphoma * Treatment with a systemic immunosuppressive regimen within the previous 30 days; systemic prednisone (or its equivalent) of ≤ 10 mg daily is, however, permitted. * Any implantable corticosteroid-eluting device (e.g., Retisert™, Posurdex®, Medidur™, I-vation™ TA intravitreal implant) * Subjects who periodically require high-dose systemic steroid treatment (e.g., for exacerbation of chronic obstructive pulmonary disease). * Subjects who have received treatment with a monoclonal antibody or any other biologic therapy within the previous 90 days or alemtuzumab within the previous 12 months * History of herpes zoster or varicella infection within 6 weeks prior to enrollment, or chicken pox exposure within 21 days before enrollment * Seropositivity for human immunodeficiency virus (HIV) * Previous exposure or known contraindication to administration of cyclosporine * Recipients of a solid organ transplant * Currently pregnant or lactating * Active, extraocular and/or systemic infection requiring the prolonged or chronic use of antimicrobial agents or the presence of active hepatitis A, B or C * Severe anemia (hemoglobin \< 6 g/dL), leukopenia (white blood cell count \[WBC\] \< 2500 mm3), thrombocytopenia (platelet count \< 80,000 mm3), polycythemia (hematocrit \[Hct\] \> 54% \[male\] or Hct \> 49% \[female\]) or clinically significant coagulopathy * Current malignancy or a history of malignancy (within the previous 5 years) except non-metastatic basal or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix that has been treated successfully * Active peptic ulcer disease * Co-morbid conditions that require immunosuppression